TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tonix Pharmaceuticals Holding Corp (TNXP) does not present a strong buy opportunity for a beginner, long-term investor at this time. The technical indicators are bearish, options data suggests limited bullish sentiment, and financial performance, while showing some improvement, still reflects significant losses. With no recent news or catalysts, and no strong signals from Intellectia Proprietary Trading Signals, it is advisable to hold off on investing in this stock currently.
The technical indicators for TNXP are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 37.78, and moving averages are in a bearish configuration (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 14.095) with resistance at R1: 15.555. There is no clear upward momentum.
These are positive signs of operational improvement.
The company remains unprofitable with a net income of -$32.01M in Q3 2025, despite a 125.22% YoY improvement. EPS dropped significantly by -84.31% YoY, and there is no recent news or event-driven catalysts to drive the stock price.
In Q3 2025, revenue increased by 16.58% YoY to $3.29M, and gross margin improved to 58.45%. However, the company remains unprofitable with a net income of -$32.01M, and EPS dropped to -3.59, down -84.31% YoY. While there are signs of operational improvement, the financials remain weak overall.
No recent analyst ratings or price target changes are available for TNXP, making it difficult to gauge Wall Street sentiment.
